Registry or randomization - must it be evidence or could it be coincidence? [0.03%]
注册还是随机化——必须基于证据还是可能只是巧合？
Olga Radulova,Florian Oehme,Sandra Korn et al.
Olga Radulova et al.
Over the years, clinical registries and randomized controlled trials gained acceptance. With increasing experience, it was possible to obtain knowledge of benefits and limitations in both designs. During the last years, the research focus w...
Luis Fernando Tintinago-Londoño,Estephania Candelo,Tania Guzmán et al.
Luis Fernando Tintinago-Londoño et al.
Objectives: Reconstructing the hypopharynx while preserving the larynx poses a complex surgical challenge due to the limited space and the high position of the hypopharynx in the neck. We present our experience with hypop...
Deep learning for automated boundary detection and segmentation in organ donation photography [0.03%]
深度学习在器官捐献摄影中的自动边界检测与分割技术研究
Georgios Kourounis,Ali Ahmed Elmahmudi,Brian Thomson et al.
Georgios Kourounis et al.
Objectives: Medical photography is ubiquitous and plays an increasingly important role in the fields of medicine and surgery. Any assessment of these photographs by computer vision algorithms requires first that the area ...
The evolving role of esophageal surgery - advancements, challenges, and the path forward [0.03%]
食管手术不断变化的角色-进展、挑战和前进的道路
Stefan P Mönig,Mickael Chevallay
Stefan P Mönig
Marcel A Schneider,Diana Vetter,Christian A Gutschow
Marcel A Schneider
Subepithelial esophageal tumors (SET) are normally benign intramural esophageal lesions of mesenchymal origin. Although rare, the incidence of SET has increased in recent decades due to the more widespread use of endoscopy and diagnostic im...
Thorsten Goetze,Mickael Chevallay,Michel Dosch et al.
Thorsten Goetze et al.
Half of the patients with esophageal cancer, cancer of the gastro-esophageal junction and gastric cancer present metastasis at the time of diagnosis. In addition, even patients originally thought to be free of metastasis will present metach...
Neoadjuvant treatment of esophageal cancer: chemotherapy, chemoradiation, immunotherapy, and future trends of therapy [0.03%]
食管癌的新辅助治疗：化疗，化放疗，免疫疗法和治疗的未来趋势
Freschta Malekzada,Miljana Vladimiriov,Michael Leitz et al.
Freschta Malekzada et al.
In the Western hemisphere, nonmetastatic locally advanced esophageal carcinoma is mostly treated in multimodal therapy protocols according to current therapy guidelines. In squamous cell carcinoma of the esophagus, neoadjuvant chemoradiatio...
Yvonne Huber,Markus Moehler,Anica Högner
Yvonne Huber
The therapeutic landscape in nearly every therapeutic line in advanced/metastatic patients with squamous cell carcinoma (SCC) and esophagogastric adenocarcinoma (EGC) is enriched by recent approvals of immune checkpoint inhibitors (ICIs). I...
Active surveillance in patients with a complete clinical response after neoadjuvant chemoradiotherapy for esophageal- and gastroesophageal junction cancer [0.03%]
新辅助化疗放疗后食管和食胃结合部癌完全临床缓解患者的主动监测
Tamara J Huizer,Sjoerd M Lagarde,Joost J M E Nuyttens et al.
Tamara J Huizer et al.
Neoadjuvant chemoradiotherapy in patients with esophageal- and gastroesophageal junction cancer induces tumor regression. In approximately one fourth of patients, this leads to a pathological complete response in the resection specimen. Hen...
Verena Tripke,Vladimir J Lozanovski,Carolina Mann et al.
Verena Tripke et al.
Esophageal cancer is an aggressive tumor entity, and oncologic esophagectomy with two-field lymphadenectomy after perioperative chemotherapy or chemoradiotherapy is the standard of care for curative treatment. Oncological esophagectomy is a...